Ignite Creation Date:
2024-05-06 @ 7:22 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05982886
Status:
COMPLETED
Last Update Posted:
2023-08-09
First Post:
2023-08-01
Brief Title:
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a retrospective observational study of patients with advanced breast cancer BC This non-interventional study was conducted using discrete structured data and medical record abstraction if needed from patients treated at Texas Oncology the designated research organization and a community oncology practice The first date of a new diagnosis of advanced BC de novo or progressed to advanced BC defined the study index date To allow for an adequate potential duration of follow-up retrospectively observed after the index date over which PIK3CA testing and treatment patterns was observed a minimum follow-up opportunity of 6 months after the diagnosis of advanced BC at the time of data pull andor abstraction was required
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None